Vir Biotechnology, Inc.
VIR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001706431
No open-market purchases or sales by Vir Biotechnology, Inc. insiders were filed in the last 90 days; 237 institutions reported holding it in 13F filings for Q2 2026, worth $1.49B in total; no superinvestor holds it.
Holders of 5% or more of VIR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Vir Biotechnology, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 10.80%14.8M shares | – | Apr 28, 20251 filing | Apr 28, 2025 | SEC |
| ARCH Venture Fund IX, L.P. | 13D/A | 8.50%13.5M shares | – | Mar 3, 20261 filing | Mar 3, 2026 | SEC |
| SB Investment Advisers (UK) Ltd | 13G/A | 6.50%10.9M shares | −2.90 ppfrom 9.40% | Feb 17, 20262 filings | May 15, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.79%9.26M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Vir Biotechnology, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 20269:00 PM ET | SB Investment Advisers (UK) Ltdand 2 others | 13G/A | 6.50%10.9M shares | −2.90 ppfrom 9.40% | Mar 31, 2026 | SEC |
| Apr 29, 20263:50 PM ET | Vanguard Portfolio Management LLC | 13G | 5.79%9.26M shares | New | Mar 31, 2026 | SEC |
| Mar 27, 20261:55 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Mar 3, 20265:00 PM ET | ARCH Venture Fund IX, L.P.and 7 others | 13D/A | 8.50%13.5M shares | – | Feb 27, 2026 | SEC |
| Feb 17, 20265:00 PM ET | SB Investment Advisers (UK) Ltdand 2 others | 13G/A | 9.40%13.1M shares | – | Dec 31, 2025 | SEC |
| Apr 28, 20251:02 PM ET | BlackRock, Inc. | 13G/A | 10.80%14.8M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Vir Biotechnology, Inc. shares.
No Form 144 notices for Vir Biotechnology, Inc. are on file.